JP2024161376A5 - - Google Patents

Download PDF

Info

Publication number
JP2024161376A5
JP2024161376A5 JP2024114477A JP2024114477A JP2024161376A5 JP 2024161376 A5 JP2024161376 A5 JP 2024161376A5 JP 2024114477 A JP2024114477 A JP 2024114477A JP 2024114477 A JP2024114477 A JP 2024114477A JP 2024161376 A5 JP2024161376 A5 JP 2024161376A5
Authority
JP
Japan
Prior art keywords
drawings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024114477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024161376A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/018335 external-priority patent/WO2019161290A1/en
Application filed filed Critical
Publication of JP2024161376A publication Critical patent/JP2024161376A/ja
Publication of JP2024161376A5 publication Critical patent/JP2024161376A5/ja
Pending legal-status Critical Current

Links

JP2024114477A 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたCas9システム Pending JP2024161376A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862631304P 2018-02-15 2018-02-15
US62/631,304 2018-02-15
US201862720525P 2018-08-21 2018-08-21
US62/720,525 2018-08-21
PCT/US2019/018335 WO2019161290A1 (en) 2018-02-15 2019-02-15 Engineered cas9 systems for eukaryotic genome modification
JP2020531575A JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム
JP2022083820A JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022083820A Division JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム

Publications (2)

Publication Number Publication Date
JP2024161376A JP2024161376A (ja) 2024-11-19
JP2024161376A5 true JP2024161376A5 (https=) 2025-01-14

Family

ID=65995829

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020531575A Active JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム
JP2024114477A Pending JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたCas9システム

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020531575A Active JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム

Country Status (11)

Country Link
US (2) US10767193B2 (https=)
EP (1) EP3752607A1 (https=)
JP (3) JP7109547B2 (https=)
KR (3) KR102465067B1 (https=)
CN (1) CN111902536B (https=)
AU (3) AU2019222568B2 (https=)
BR (1) BR112020010479A2 (https=)
CA (2) CA3084020C (https=)
IL (2) IL321024A (https=)
SG (1) SG11202007382TA (https=)
WO (1) WO2019161290A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US11111492B2 (en) * 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
CA3129835A1 (en) 2019-02-15 2020-08-20 Sigma-Aldrich Co. Llc Crispr/cas fusion proteins and systems
CA3130789A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
WO2021127209A1 (en) 2019-12-17 2021-06-24 Sigma-Aldrich Co. Llc Genome editing in bacteroides
GB2594339B (en) * 2020-02-14 2023-02-08 Metagenomi Inc Enzymes with RUVC domains
CA3163463A1 (en) * 2020-03-11 2021-09-16 Fuqiang Chen High fidelity spcas9 nucleases for genome modification
GB2608292B (en) * 2020-03-31 2024-02-14 Metagenomi Inc Class II, type II CRISPR systems
CN112159801B (zh) * 2020-07-13 2022-11-15 复旦大学 SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用
EP4230737A4 (en) * 2020-09-21 2024-07-24 Korea University Research and Business Foundation NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF
JP2023549339A (ja) * 2020-11-06 2023-11-24 ペアワイズ・プランツ・サーヴィシズ,インコーポレイテッド 対立遺伝子の、rnaによりコードされるdna置換のための組成物および方法
CN113717960B (zh) * 2021-08-27 2023-07-18 电子科技大学 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
CN114657181B (zh) * 2022-04-01 2023-08-25 安徽大学 一种靶向H1.4的sgRNA以及H1.4基因编辑方法
CN119948064A (zh) * 2022-09-23 2025-05-06 庄伟哲 靶向整合素 αIIbβ3的含组织纤维溶酶原活化剂或其变异体的融合蛋白质及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
EP3241902B1 (en) * 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3363902B1 (en) * 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
AU2013359262C1 (en) * 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
EP3004370B1 (en) 2013-06-05 2024-08-21 Duke University Rna-guided gene editing and gene regulation
US9074199B1 (en) * 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
JP2017503514A (ja) * 2014-01-24 2017-02-02 ノースカロライナ ステート ユニバーシティーNorth Carolina State University Cas9ターゲッティングをガイドする配列に関する方法および組成物
US11242525B2 (en) * 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
EP3633032A3 (en) * 2014-08-28 2020-07-29 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
WO2016054326A1 (en) * 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
LT3604527T (lt) 2016-06-02 2021-06-25 Sigma-Aldrich Co., Llc Programuojamų, dnr surišančių baltymų panaudojimas tiksliniam genomo modifikavimui pagerinti
US10017760B2 (en) 2016-06-24 2018-07-10 Inscripta, Inc. Methods for generating barcoded combinatorial libraries
JP7305534B2 (ja) 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
JP7182545B2 (ja) * 2016-12-14 2022-12-02 ヴァーヘニンゲン ユニヴェルシテット 熱安定性cas9ヌクレアーゼ
KR102523217B1 (ko) * 2017-07-11 2023-04-20 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
KR20200036912A (ko) * 2017-07-31 2020-04-07 리플렉션 바이오테크놀러지스 리미티드 안과 질환을 위한 세포 모델 및 치료요법

Similar Documents

Publication Publication Date Title
JP2024161376A5 (https=)
JP2024116190A5 (https=)
JP2023171775A5 (https=)
JP2024114921A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2025138632A5 (https=)
JP2025176106A5 (https=)
JP2023145572A5 (https=)
JP2025138641A5 (https=)
JP2023181322A5 (https=)
JP2024129139A5 (https=)
JP2025098156A5 (https=)
JP2025118629A5 (https=)
JP2024045126A5 (https=)
JP2025090801A5 (https=)
JP2025094038A5 (https=)
JP2024149687A5 (https=)
JP2025084821A5 (https=)
JP2024099716A5 (https=)
JP2026004279A5 (https=)
JP2023093656A5 (https=)
JP2024099585A5 (https=)
JP2023085264A5 (https=)
JP2023156274A5 (https=)